Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia.
about
Treatment of Gram-positive infections in critically ill patientsHigh vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis.Is vancomycin MIC creep a worldwide phenomenon? Assessment of S. aureus vancomycin MIC in a tertiary university hospitalEpidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitalsHow to treat VAP due to MDR pathogens in ICU patients.Year in review in Intensive Care Medicine 2011. II. Cardiovascular, infections, pneumonia and sepsis, critical care organization and outcome, education, ultrasonography, metabolism and coagulationDaptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE).Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.Clonal distribution and possible microevolution of methicillin-resistant Staphylococcus aureus strains in a teaching hospital in Malaysia.The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia.Year in review 2010: Critical Care--Infection.The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis.Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy.Antimicrobial resistance in internal medicine wards.Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin.Susceptibility testing and reporting of new antibiotics with a focus on tedizolid: an international working group report.Prevention of Staphylococcus aureus Ventilator-Associated Pneumonia: Conventional Antibiotics Won't Cut It.Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.Pharmacokinetic Characteristics and Clinical Outcomes of Vancomycin in Young Children With Various Degrees of Renal Function.Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.Development and stability studies of novel liposomal vancomycin formulations.Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing.Update on ventilator-associated pneumonia.Dalbavancin treatment in a deep sternal wound MRSA infection after coronary artery bypass surgery: a case report.WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.Initial Vancomycin Dosing Protocol to Achieve Therapeutic Serum Concentrations in Patients Undergoing Hemodialysis
P2860
Q27015976-67D244F7-C067-4111-90E3-A45A26AD93FEQ34454418-22AF6FD6-A067-4B27-9FC9-A96AB43E59F8Q34591873-C8BBFBDA-C2CE-47D5-A4F9-F35AAAF4008EQ34999500-1A19B176-51EC-4E9E-B29C-CE8D621F3A65Q35457068-2BBC2872-7E77-42B6-9B49-8CB1295BE179Q35795215-9E8828AE-0E21-47BA-80CF-33AC19EB9DD1Q35802607-4A858413-17C3-4076-969E-91C5A0BD80DFQ36073410-501B95E7-596E-4E4B-B122-7FE3DE84656DQ36565462-BE7627FD-7871-4713-89E9-273A9D4DC9DEQ36782390-4C973860-A05C-4470-977C-DA54D3A57475Q37366784-1C66C4A4-5D8B-4F0F-A3F3-06E3F5CA07F6Q37966018-4E6FCAD9-5856-4B8B-9EC0-9AB7DA5298C5Q37981103-CB60B79B-59DE-4159-9653-5E7AD38D75E9Q37982066-EDE9178B-A3E4-4F16-A357-4F39AD70CB0DQ38052855-58F484AC-2660-4EFD-BF92-2F634FCE1C80Q38428770-9C9B496C-1F6E-4527-93D0-118D90DD7679Q38627072-D8EFAA53-426A-4E28-A92C-C8035D1D1A06Q38641810-9F57B22A-4C94-40D9-8E2F-1E75A377B602Q40346731-10A993EB-5486-43DF-AB5A-BEA832E71284Q40394687-02B3DB4A-05D0-4618-9FAE-7E4E6980B301Q40964689-B23BCD1E-D04D-4DCD-8E2C-8B9135F1933AQ41654159-2D8357BE-9018-4F4E-8F93-4FC624356BBCQ41915895-5761266B-C7DD-4823-8E7D-FBE97E6E487DQ44923981-23559FB9-D159-4C16-B349-38F7C822F49DQ47129727-9251D381-829F-4E36-AA8D-A808347E6B4EQ48301411-9C03B5C2-F35F-4D64-ADE1-239184AB7472Q51247058-AB062434-F9FA-44A2-A6FC-04754F43FC90Q57238274-94BD4643-7272-4447-8272-47F0864EB6AB
P2860
Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@en
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@nl
type
label
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@en
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@nl
prefLabel
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@en
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@nl
P2093
P2860
P1476
Relationship between the MIC o ...... ith MRSA nosocomial pneumonia.
@en
P2093
Chae-Man Lim
Eun Young Choi
Jin Won Huh
Sang-Bum Hong
Sang-Ho Choi
Sung-Han Kim
Yang Soo Kim
Younsuck Koh
P2860
P2888
P304
P356
10.1007/S00134-011-2130-7
P577
2011-01-21T00:00:00Z
P6179
1024635538